HK1199290A1 - 用於治療和診斷乳腺癌的方法和組合物 - Google Patents

用於治療和診斷乳腺癌的方法和組合物

Info

Publication number
HK1199290A1
HK1199290A1 HK14112746.6A HK14112746A HK1199290A1 HK 1199290 A1 HK1199290 A1 HK 1199290A1 HK 14112746 A HK14112746 A HK 14112746A HK 1199290 A1 HK1199290 A1 HK 1199290A1
Authority
HK
Hong Kong
Prior art keywords
diagnosis
compositions
treatment
methods
breast cancer
Prior art date
Application number
HK14112746.6A
Other languages
English (en)
Inventor
Karen Chapman
Joseph Wagner
Michael West
Jennifer Lorrie Kidd
Maria J Prendes
Original Assignee
Oncocyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncocyte Corp filed Critical Oncocyte Corp
Publication of HK1199290A1 publication Critical patent/HK1199290A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
HK14112746.6A 2011-08-16 2014-12-19 用於治療和診斷乳腺癌的方法和組合物 HK1199290A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524170P 2011-08-16 2011-08-16
US201161553706P 2011-10-31 2011-10-31
PCT/US2012/051235 WO2013025952A2 (en) 2011-08-16 2012-08-16 Methods and compositions for the treatment and diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
HK1199290A1 true HK1199290A1 (zh) 2015-06-26

Family

ID=47715702

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112746.6A HK1199290A1 (zh) 2011-08-16 2014-12-19 用於治療和診斷乳腺癌的方法和組合物

Country Status (9)

Country Link
US (1) US20140235486A1 (zh)
EP (1) EP2744917A4 (zh)
JP (2) JP2014525240A (zh)
KR (1) KR20140057331A (zh)
CN (1) CN104080924A (zh)
AU (1) AU2012296405B2 (zh)
CA (1) CA2844805A1 (zh)
HK (1) HK1199290A1 (zh)
WO (1) WO2013025952A2 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138661A1 (en) * 2013-03-08 2014-09-12 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation
AU2015277059B2 (en) * 2014-06-18 2021-06-17 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
US9784743B2 (en) 2015-06-22 2017-10-10 Rhode Island Hospital, A Lifespan-Partner Collagens as markers for breast cancer treatment
CN105255927B (zh) * 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
WO2017061953A1 (en) * 2015-10-05 2017-04-13 Agency For Science, Technology And Research Invasive ductal carcinoma aggressiveness classification
US11401558B2 (en) 2015-12-18 2022-08-02 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
EP3491129A4 (en) * 2016-07-29 2020-01-22 Roger L. Kaspar METHODS OF TREATING OSMIDROSIS
CN109422810A (zh) * 2017-08-24 2019-03-05 孙立春 全人源或人源化bombesin受体GRPR单克隆抗体药物或诊断试剂的开发及应用
US20200063202A1 (en) * 2018-04-25 2020-02-27 Juneau Biosciences, L.L.C. Methods of using genetic markers associated with endometriosis
WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US20210199660A1 (en) * 2019-11-22 2021-07-01 10X Genomics, Inc. Biomarkers of breast cancer
CN112501303A (zh) * 2020-12-14 2021-03-16 西北工业大学 分子标志物col11a1及其在乳腺癌药物中的应用
CN117916596A (zh) * 2021-09-10 2024-04-19 格里尔公司 生物流体中靶分子的分析方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514209B2 (en) * 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20070218512A1 (en) * 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
JP2010524456A (ja) * 2007-04-16 2010-07-22 イプソゲン 乳癌に罹患している雌哺乳動物に対する臨床転帰の傾向を評価する方法
WO2008132167A2 (en) * 2007-04-26 2008-11-06 Dublin City University Diagnostic, prognostic and/or predictive indicators of breast cancer
EP2163649A1 (en) * 2008-09-11 2010-03-17 Fédération Nationale des Centres de Lutte Contre le Cancer Molecular classifier for evaluating the risk of metastasic relapse in breast cancer
US8999648B2 (en) * 2009-10-01 2015-04-07 Signal Genetics, Inc. System and method for classification of patients
CN101701220A (zh) * 2009-11-13 2010-05-05 南开大学 一种乳腺癌相关基因c10rf64及其应用
US20110123990A1 (en) * 2009-11-23 2011-05-26 Baker Joffre B Methods To Predict Clinical Outcome Of Cancer
WO2011109637A1 (en) * 2010-03-03 2011-09-09 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles

Also Published As

Publication number Publication date
WO2013025952A2 (en) 2013-02-21
EP2744917A2 (en) 2014-06-25
WO2013025952A3 (en) 2014-05-08
EP2744917A4 (en) 2015-10-14
US20140235486A1 (en) 2014-08-21
JP2019030300A (ja) 2019-02-28
CN104080924A (zh) 2014-10-01
KR20140057331A (ko) 2014-05-12
CA2844805A1 (en) 2013-02-21
AU2012296405A1 (en) 2014-02-27
AU2012296405B2 (en) 2016-03-17
JP2014525240A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
HK1199099A1 (zh) 用於治療和診斷癌症的方法和組合物
HK1199100A1 (zh) 用於治療和診斷結直腸癌的方法和組合物
HK1254859A1 (zh) 治療乳腺癌的方法
HK1199290A1 (zh) 用於治療和診斷乳腺癌的方法和組合物
HK1202313A1 (zh) 治療和診斷膀胱癌的方法和組合物
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
HK1201413A1 (zh) 乳癌的治療
IL237558A0 (en) Methods for treating locally advanced breast cancer
EP2890815A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2723924A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
HK1200739A1 (zh) 用於治療癌症的診斷方法和組合物
HK1178074A1 (zh) 用於腫瘤診斷和治療的組合物和方法
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HK1197276A1 (zh) 治療及診斷膀胱癌的方法和組合物
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP2591363A4 (en) DIAGNOSIS AND TREATMENT OF BREAST CANCER
IL237844B (en) Radiolabeled grpr antagonists for diagnostic imaging and treatment of grpr-positive cancer
HK1201045A1 (zh) 用於腫瘤診斷和治療的組合物和方法
PL2605764T3 (pl) Kompozycje do leczenia nowotworu
EP2766045A4 (en) TREATMENT OF BREAST CANCER WITH A COMPAGNION DIAGNOSIS
EP2928456A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT